Adenovirus-mediated gene transfer of interferon α improves dimethylnitrosamine-induced liver cirrhosis in rat model

Gene Therapy

Volumn 10, Issue 9, 2003, Pages 765-773

  Suzuki, K ^a,b   Aoki, K ^a   Ohnami, S ^a   Yoshida, K ^a   Kazui, T ^b   Kato, N ^c   Inoue, K ^d   Kohara, M ^d   Yoshida, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Adenovirus; Gene transfer; Hepatitis C virus; Interferon; Liver cirrhosis

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; DIMETHYLNITROSAMINE; RECOMBINANT ALPHA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOXICITY; FEASIBILITY STUDY; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE TRANSFER; GENETIC TRANSDUCTION; HEPATITIS C; LIVER CIRRHOSIS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; DIMETHYLNITROSAMINE; FIBROSIS; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; HEPATITIS C VIRUS;

EID: 0038485519     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301949     Document Type: Article

References (49)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455.
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
3. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26: 128S-132S.
4. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology 1997; 26: 143S-151S.
5. Di Bisceglie AM et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
6. Poynard T et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
7. Fort J et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998; 29: 263-270.
8. Camps J et al. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17: 390-396.
9. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324: 933-940.
10. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43: 2573-2576.
11. Okanoue T et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653-659.
12. Schvarcz R et al. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991; 11: 30-38.
13. Yagura M et al. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35: 105-111.
14. Uemura I. Pharmacokinetics of recombinant human interferon alpha in rat. Kiso to Rinsho 1985; 19: 205-212.
15. Nakamura T, Akiyoshi H, Saito I, Sato K. Adenovirus-mediated gene expression in the septal cells of cirrhotic rat livers. J Hepatol 1999; 30: 101-106.
16. Jezequel AM et al. A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J Hepatol 1987; 5: 174-181.
17. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-1835.
18. Jenkins SA et al. A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J Hepatol 1985; 1: 489-499.
19. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985; 33: 737-743.
20. Bruck R et al. Prevention of hepatic cirrhosis in rats by hydroxyl radical scavengers. J Hepatol 2001; 35: 457-464.
21. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportion of imino acid. Arch Biochem Biophys 1961; 93: 440-447.
22. Fujimoto J, Kaneda Y. Reversing liver cirrhosis: impact of gene therapy for liver cirrhosis. Gene Ther 1999; 6: 305-306.
23. Lee HS et al. Expression of matrix metalloproteinases in spontaneous regression of liver fibrosis. Hepatogastroenterology 2001; 48: 1114-1117.
24. Watanabe T et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000; 33: 224-235.
25. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266: 14064-14071.
26. Poncelet AC, Schnaper HW. Regulation of human mesangial cell collagen expression by transforming growth factor-beta 1. Am J Physiol 1998; 275: F458-F466.
27. Ikeda K et al. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999; 29: 1760-1767.
28. Iredale JP et al. Tissue Inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176-184.
29. Qi Z et al. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 1999; 96: 2345-2349.
30. Ueki T et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.
31. Rudolph KL et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-1258.
32. Salgado S et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2001; 2: 545-551.
33. Takayama H et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94: 701-706.
34. Eto T, Takahashi H. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat Med 1999; 5: 577-581.
35. Protzer U et al. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc Natl Acad Sci USA 1999; 96: 10818-10823.
36. de Roos WK et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997; 4: 55-62.
37. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998; 9: 1975-1981.
38. Garcia-Banuelos J et al. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther 2002; 9: 127-134.
39. Nakatani T et al. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut 2000; 47: 563-570.
40. Akli S et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3: 224-228.
41. Hermens WT, Verhaagen J. Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. Hum Gene Ther 1997; 8: 1049-1063.
42. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30.
43. Haecker SE et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907-1914.
44. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
45. Langer R. Drug delivery and targeting. Nature 1998; 392: 5-10.
46. Miyake S et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320-1324.
47. Aoki K et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000; 1: 555-565.
48. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
49. Aoki K et al. Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther 2001; 8: 508-514.